% | $
Quotes you view appear here for quick access.

Pinetree Capital Ltd. Message Board

alpenland 5 posts  |  Last Activity: Nov 23, 2015 12:55 PM Member since: Feb 7, 2005
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • alpenland by alpenland Nov 23, 2015 12:55 PM Flag

    BlackRock, Inc., Wilmington, DE, United States
    Triggering event:
    Exceeding Threshold
    Threshold(s) crossed or reached:5%
    Date at which the threshold is crossed or reached:
    Total amount of voting rights: 6.35%

  • 190 #$%$ buy
    (from actually 163.20#$%$)

  • alpenland by alpenland Nov 11, 2015 11:28 AM Flag

    this is the fulfilled prognosis of GS. Now are the shares changing cheapest to SNY :-((

  • alpenland by alpenland Nov 5, 2015 4:23 AM Flag

    Societe Generale Q3 Profit Rises

    PARIS (dpa-AFX) - French lender Societe Generale SA (SCGLF.PK, SCGLY.PK) said its third-quarter group net income improved to 1.127 billion euros from 882 million euros in the prior year. Adjusted for revaluation of own financial liabilities and DVA, group net income was 905 million euros, compared to 884 million euros last year.

    Operating income climbed to 2.39 billion euros from last year's 1.96 billion euros. Net banking income increased 8.3 percent to 6.36 billion euros.

    Commenting on the results, Frédéric Oudéa, CEO, said, 'The Societe Generale Group has posted sound results in Q3 2015 on the back of a good commercial performance and the continued control of costs and risks. We have provided further evidence of our growth potential against the backdrop of a recovery in Europe, with a substantial increase in our Retail Banking activities, in France with record growth in new customers and also internationally.'

  • Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration or FDA has accepted the company's New Drug Application or NDA and granted Priority Review for alectinib, an oral investigational anaplastic lymphoma kinase or ALK inhibitor, for the treatment of people with ALK-positive, locally advanced or metastatic non-small cell lung cancer or NSCLC who have progressed on or are intolerant to crizotinib.

    Alectinib was granted Breakthrough Therapy Designation by the FDA in June 2013 for people with ALK-positive NSCLC whose disease progressed on crizotinib...

0.050.00(0.00%)Nov 27 2:54 PMEST